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Introduction
Scars are a major disease burden on morbidity, 
mortality and quality of life.1,2 In this second 
manuscript, we review our centre’s multimodality 
approach for scar management, focusing on scar 
hypertrophy, keloid, acne pigmentation and 
vascular scarring, based upon experience and 
backed by evidence.
Lasers and ancillary treatments  
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and acne scars
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Abstract
The formation of a wide range of excessive scars following various skin injuries is a natural consequence of 
healing. Scars resulting from surgery or trauma affect approximately 100 million people per annum in the 
developed world and can have profound physical, aesthetic, psychological and social consequences. Thus, 
scar treatment is a priority for patient and physician alike. Laser treatment plays an important role in scar 
management with additional support from ancillary modalities. Subsequent to part 1: Burns scars, part 2 
focuses on our strategies and literature review of treatment of keloid, hypertrophic, pigmented and acne scars 
where lasers are used in conjunction with other measures, and illustrated with case studies.
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Lay Summary
Scars can result as part of the normal healing process after a burn or other trauma such as surgery or injury. 
However, there is a range of scarring from ‘good’ to ‘bad’ depending on various features of the scars. Some 
can be can be lumpy and raised (hypertrophic and keloid scars), have changes in pigmentation (increased 
or decreased colouration) or have specific features related to the cause (for instance acne scars, burns scars). 
We review the senior author’s experience over twenty years in treating scars with a range of treatments in 
conjunction with lasers. This is the second and final article in the series looking at 4 main aspects of scarring. 
In part 1, the focus was burns scars.
In Part 2, we now focus on hypertrophic and keloid scars (thickened raised scars); pigmented scars and 
acne scars. Lasers play an important role in managing a variety of scars in our practice, which work best in 
combination with other treatments as described.
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Hypertrophic scars and keloids
Hypertrophic scars are typically confined within 
the borders of the initial insult and present as 
immature, linear or widespread. Immature 
hypertrophic scars are red, on occasion pruritic 
or painful, mildly raised and are in the process 
of remodelling. Usually, these scars mature to 
flat scars. Linear scars are most commonly a 
result of a healed laceration, or surgical incision. 
They tend to improve and flatten only slowly 
with time and hence patients seek help to reduce 
the symptoms of itchiness and poor appearance. 
All types may regress to varying degrees sponta-
neously with time.3,4 Hypertrophic scar patho-
genesis may be related to atypical extracellular 
matrix metabolism secondary to abnormal and 
exaggerated fibroblastic activation.5,6 This mani-
fests histologically as well organised type III 
collagen but with an overexpression of both types 
I and III, profibrotic pyridinoline type collagen-
ous crosslinkages, fibronectin deposition with 
overexpression of interleukins (IL)-4–6, -13 and 
-21 and underexpresion of IL-12 and interferon 
(IFN)-γ.5,6
Keloids are defined as excessive scars that 
invade beyond the borders of the initial insult 
and do not regress spontaneously. They recur in 
45–100% of cases following excision.3,4 This is 
due to the fact that the new closure is exposed to 
the same mechanical, immunological and bio-
chemical forces as the original scar.3–6 Areas par-
ticularly prone include the earlobes, chest, 
shoulders, upper back and posterior neck. Minor 
keloids are focally raised, pruritic scars that can 
occur up to one year following the initial injury. 
Major keloids are large, raised (>5 mm), dark 
red scars associated with pain and pruritis and 
continue to increase in size over years.
Although similar approaches to both hyper-
trophic and keloid scarring exist in the literature, 
there is no universally accepted regimen. Most 
commonly used techniques lack well-designed 
randomised controlled studies.
Prophylaxis of hypertrophic and keloid scars
Meticulous wound debridement, removal of for-
eign and necrotic material, tension-free closure 
with the least reactive suture material and every 
attention to avoid infection are effective preven-
tive measures.7,8 After wound closure, methods 
include tension reduction either mechanically9,10 
or neurotoxically mediated,11 hydrating occlusive 
silicone gel dressings12,13 and pressure garment 
therapy.7,14 The earlier this treatment occurs for 
abnormal immature scars with intact epithelium, 
the more favourable the outcome. The transition 
to a formal treatment regime develops when a 
true hypertrophic scar or keloid, and not an 
immature hypertrophic scar, has been diagnosed. 
Conventional treatment of both hypertrophic 
scars and keloids commonly involves massage,15–18 
pressure therapy,19–23 hydrating occlusive silicone 
dressings,24–29 corticosteroid injection,30–32 surgi-
cal excision33–35 and radiotherapy,36–39 alone or in 
combination.30,31 Only hydrating occlusive sili-
cone dressing and corticosteroid injection have 
been demonstrated effective in randomised con-
trolled trials.31,40 A comprehensive review of the 
strength of the evidence in the other first line 
modalities is available elsewhere41 and is beyond 
the scope of this chapter.
Prophylaxis of hypertrophic and keloid scars
Corticosteroid injection. Corticosteroid injec-
tion, either alone or in combination with other 
agents, has become one of the most widely prac-
tised treatment modalities for hypertophic scars 
and keloids.42,43 These are normally administered 
intralesionally in the form of insoluble triamci-
nolone acetonide (0–40 mg mL−1). Injections are 
performed every four to six weeks until pruritic 
and pain-related symptoms subside and the scar 
flattens. Response rates vary (50–100% with a 
recurrence rate of 9–50%44,45). Complication are 
common and 63% experience localised dermal 
atrophy, ulceration, hypopigmentation or telan-
giectasia.46 Significant pain may be controlled by 
the addition of local anaesthetic. As monother-
apy, coticosteroids are most effective for younger 
keloids, which may completely flatten while 
older keloids are more resistant.47 Given these 
limitations, other agents have been used in com-
bination with corticosteroids to further modulate 
the hyperproliferative response.
Fluorouracil. The senior author advocates 
the combined use of 5-Florouracil (5-FU), a 
pyrimidine analogue, commonly used as an anti-
metabolite chemotherapy reagent. It inhibits thy-
midylate synthase activity. First used to reduce 
subconjunctival scarring in the context of glau-
coma filtering surgery in 1984,48,49 it was later 
used as both a monotherapy and in combination 
with corticosteroids for the treatment of hyper-
trophic scars and keloids.32,50 Combined therapy 
with concentrations in the range of 40–50 mg 
mL−1 has been found to be more efficacious 
than 5-FU monotherapy,51–55 with no additional 
complications.56 Acting intracellularly, it pro-
motes fibroblastic apoptosis, without necrosis, via 
inhibition of DNA synthesis in hyperproliferative 
and metabolically active cells. More recently, 
Huang et al. demonstrated the possibility of low 
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dose 5-FU at 1 mg mL−1 and triamcinolone work 
together to inhibit fibroblastic proliferation, type 
I collagen deposition and matrix metalloprotein-
ase-2 induction in vitro, and promote apopto-
sis.57,58 Our current approach, however, is to use 
conventional doses of 50 mg mL−1 injected intral-
esionally in combination with 10–40 mg mL−1 
depending on scar resistance and extent every 
four to six weeks until the scar is flat, soft and 
symptom-free. The scar is not injected to the 
point of blanching to avoid ischaemia, ulceration 
and potential deterioration. Once a plateau is 
reached, the injections may be given between 
increasingly longer intervals titrated to response. 
All patients are informed of the fact that initial 
injections are uncomfortable due to the dense 
nature of the scar and subsequent injections 
becoming less so. In addition, local complica-
tions such as post-injection pain, ulceration and 
burning are outlined as is the theoretical risk of 
5-FU-induced neutropenia and fetal complica-
tions if pregnant. The treatment is not performed 
during pregnancy or in those patients with bone 
marrow suppression.
Excision, combined with postoperative 5-FU 
and triamcinolone injection, can be effective,33 
but must be considered on a case-by-case basis, 
for example if a patient presents with mature 
bulky keloid disease of the earlobe or face, or a 
functionally disabling immature or early-stage 
hypertrophic scar. It must be remembered that 
hypertrophic scars mature during a period of at 
least 12 months and demonstrate decreased con-
tractures, thickening, softening and repigmenta-
tion quite often without treatment.59 Therefore, 
excision may not be warranted despite the fact 
recurrence may be low.60,61 For mature keloidal 
excision, a complete excision of all scar tissue is 
performed62,63 and closure is delivered with mini-
mal tension and suture material leaving everted 
wound margins. Indeed, the senior author has 
performed this with the ablative CO2 laser. 
Undermining however, is not recommended and 
sutures should be placed multiplanar to reduce 
tension.33 Residual lesional injection is performed 
thereafter at the time of surgery and continued at 
four- to six-week intervals titrated to response.
Intralesional cryosurgery. This technique 
evolved from simple cryosurgery, first introduced 
by Shepard and Dawber.64 Suitable for small scars 
only, liquid nitrogen contact or spray technique 
may induce vascular injury leading to anoxia, 
scar tissue necrosis, sloughing and thus scar flat-
tening.65 The process may take two to ten treat-
ment sessions with 20–30 days between each one. 
Success rates are in the range of 32–74% after 
two or more treatments, with higher response 
rates in hypertrophic scars compared to 
keloids.31,66,67 Reported complications include 
immediate blistering and pain with longer-term 
risks of dermal atrophy that can either hyper- or 
hypopigment.67,68 In contrast, intralesional cryo-
surgery involves placing a novel intralesional cry-
oneedle (Cryoshape™) within the long axis of 
the scar. The probe consists of an elongated dou-
ble-lumen uninsulated needle with a safety vent 
and a cutting, sealed, distal tip designed to 
enhance the penetration of the often dense, 
hard scar. To the proximal end of the probe is 
connected liquid nitrogen that is pressurised to 
circulate through the needle, which leads to an 
ice ball forming around the cryoneedle leaving 
the abutting scar tissue completely frozen. There 
is an apparent reduction in myofibroblasts and 
mast cells with an accompanying normalisation 
of collagen structure and organisation.69 First 
described by Weshahy in 199370 and later popu-
larised by Har-Shai et al.,69,71–77 the technique has 
shown increased efficacy over simple cryosur-
gery,71–77 with reports of clinical efficiency in the 
range of 20–75% scar volume reduction.71,78,79 
Complications include pain (although less than 
contact cryotherapy72,80), peritreatment oedema 
and epidermolysis, and temporary hypopigmen-
tation. Skin surface temperature is less effected 
in intralesional cryotherapy and thus melanocyte 
sparing is a feature accounting for a lower inci-
dence of dyschromia.81
Radiotherapy. In a small cohort of older adult 
patients, in whom other treatment options are 
declined, ionising radiation in combination with 
intralesional excision, as described, can be used 
for resistant hypertrophic scars and keloids.39 
Radiation acts to inhibit fibroblast proliferation 
and collagen synthesis, inducing apoptosis of 
proliferating cells at doses of 15–30 Gy over six 
sessions with precise dosimetry with appropriate 
shielding in the immediate postoperative 
period.31,36,37,82 Radiotherapy is restricted to older 
adults given the small but theoretical risk of car-
cinogenesis38,39 but is efficacious. Success rates in 
the literature are in the range of 25–88%,83,84 but 
this is complicated by the retrospective nature of 
studies with variable follow-up periods and poorly 
defined clinical assessment. Therefore, evidence 
remains variable and there is a need for ran-
domised prospective studies with objective clini-
cal evaluation and long-term follow-up.
Hypertrophic and keloid scar patient 
case illustrations
1. A 40-year-old woman, Fitzpatrick type II, 
presented two years following a mid-line 
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laparotomy with hypertrophic scarring. 
She complained of pruritis, pain and dis-
comfort from clothing. The shortened 
scar limited full extension and splinted 
the costal margin to the pelvis. She was 
treated with intralesional chemotherapy 
and pharmocotherapy. She underwent 
three cycles of intralesional 100 mg of 
5-FU and 40 mg of Triamcinolone six 
weeks apart. Improvement in colour, pru-
ritus and scar thickness.
2. A 78-year-old woman, Fitzpatrick type II, 
presented with a hypertrophic scar follow-
ing excision of a squamous cell carcinoma 
from her left presternal region. She com-
plained of itching, pain and the raised 
appearance. She underwent three cycles 
of intralesional 50 mg of 5-FU and 10 mg 
of Triamcinolone six weeks apart.
3. A 38-year-old man, Fitzpatrick type VI, pre-
sented with a five-year history of bilateral 
recalcitrant mandibular margin keloids 
with intense pruritus from repeated follic-
ulitis related to shaving trauma. Failed pre-
vious pharmacotherapy with stand-alone 
intralesional triamcinolone and also radio-
therapy. The patient underwent complete 
scar excision and 200 mg of 5-FU and 40 
mg of Triamcinolone injection at closure 
which was complicated on the right by 
delayed wound healing secondary to a 
small proximal wound dehiscence. Two 
months postoperatively, once all wounds 
were healed, residual keloid margin intral-
esional injection of the same mixture was 
repeated every six weeks. Nine cycles have 
passed and the time between injections 
Figure 1. Photographs are pretreatment (a), six weeks after first treatment (b) and six weeks after last treatment (c).
Figure 2. (a) At presentation; (b) 24 9 months post 
treatment showing improvement in colour, pruritus and scar 
thickness.
Figure 3. (a–c) Pre treatment and (d, e) post treatment.
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will now be lengthened. The keloid dis-
ease load has been controlled with no pru-
ritus and the patient can once again shave. 
Pre treatment (top row) and post treat-
ment (bottom row).
4. A 22-year-old woman, Fitzpatrick type V, 
presented with recalcitrant pinna keloid 
scars from a helical rim piercing with 
intense pruritus previously treated with a 
course of stand-alone intralesional triam-
cinolone. Underwent complete surgical 
excision of all scar tissue and 50 mg of 
5-FU and 10 mg of Triamcinolone injec-
tion at closure. Two months postopera-
tively, once all wounds were healed, 
margin intralesional injection of the same 
mixture was repeated every six weeks The 
keloid disease load has been controlled 
with a favourable cosmetic outcome.
5. A 27-year-old woman, Fitzpatrick type II, 
presented with presternal recalcitrant 
acne vulagaris-related keloid scars with 
intense pruritus and tenderness previ-
ously treated with topical silicone agents. 
She underwent intralesional injection of 
50 mg of 5-FU and 10 mg of Triamcinolone 
injection repeated every six weeks. The 
keloid disease load has been controlled 
after 18 injections with a favourable cos-
metic outcome and resolution of symp-
toms. Treatment is ongoing as thickening 
occurs if treatment interval exceeds six 
weeks. Pre treatment (left) and post ninth 
treatment (right).
6. A 24-year-old, Fitzpatrick type II, pre-
sented with a five-year history of mature 
static keloids related to previous acne vul-
garis inflammation in the left neck. He 
complained of the cosmetic appearance 
of the scars and difficulties shaving. A sin-
gle ablative CO2 laser treatment with the 
Ultrapulse® 2 mm true spot hand piece 
175 mJ multiple passes to ablate the keloid 
to the level of the surrounding epidermis 
was performed.
Acne scarring
Acne vulgaris is a common cutaneous disease 
with a multifactorial pathogenesis that affects a 
significant proportion of the population. The 
Figure 4. (a) Pretreatment and (b) four years post treatment, 
two years after last scar injection. Managment: intralesional 
excision and 50 mg of 5-FU and 10 mg of Triamcinolone 
injection at closure.
Figure 5. Recalcitrant acne vulgaris-related keloid scarring. 
(a) Pre treatment and (b) post treatment. Figure 6. (a, b) Mature static keloids related to previous acne 
vulgaris inflammation. (c, d) After nine months there was no 
recurrence and there was a favourable cosmetic outcome.
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condition may be divided into either come-
donal, papulopustular or congloberate acne or 
depending on severity, mild moderate or 
severe. It has a prevalence of over 80% in ado-
lescents and persists in 12–14% of cases into 
adulthood.85–91
Severe acne can lead to significant psychoso-
cial concerns, such as ostracism and withdrawal 
from society.92 Pathogenesis is multifactorial and 
includes the proliferation and colonisation of 
Propionibacterium Acne within the follicles, exces-
sive sebum production with abnormal sebum lipid 
profiles, androgen dysfunction and follicular 
hyperkeratinisation.93 As a consequence, there is 
associated infrainfundibular inflammation, follic-
ular rupture and perifollicular abcess formation. 
The resulting dermal injury stimulates the wound-
healing cascade with enzymatic degradation of 
collagen fibres and subcutaneous fat that leads to 
fibrosis and scarring.94 The severity of scarring is 
related to both the depth in the dermal piloseba-
ceous unit where inflammation and wound heal-
ing occur and the duration of inflammatory 
process, as well as an individuals genetic predispo-
sition to scarring. The final result is either a net 
loss of collagen in the form of atrophic scar types, 
which are by far the most common,94–96 or a net 
gain in the form of hypertophic scars or keloids.
Atrophic acne scars are commonly classified 
into ice pick, boxcar and rolling subtypes. Ice 
pick are the most common and are seen in 60–
70% of all patients, the remainder being either 
boxcar (20–30%) or rolling scars (15–20%).
Subtle differences between each of these sub-
types offer a guide to management options. Such 
differences include scar width, depth and three-
dimensional architecture, but they can be diffi-
cult to differentiate. Ice pick subtypes are narrow 
punctiform, very sharply demarcated epthelial-
ised tracks with a wide opening (<2.0 mm) that 
tapers as a V shape, to a deeper infundibulum in 
the deep dermis or subcutaneous fat. In some 
cases these can branch and interconnect, posing 
difficulties for surgical excision. Boxcar scars are 
larger and are characterised by round, oval or 
angular shaped depressions (1.5–4.0 mm in 
diameter), which can be shallow (0.1–0.5 mm) or 
deep (⩾0.5 mm) with well-defined wide bases 
with vertical edges and with a cross-sectional U 
shape. Finally, rolling scars are the result of der-
mal tethering to the subcutis, which are greater 
than 4.0–5.0 mm in width and give the appear-
ance of superficial shadowing with an underla-
tory M-shape appearance to otherwise texturally 
normal skin if seen in isolation. The Goodman 
and Baron qualitative scoring system is univer-
sally accepted97 is shown in Table 1.
Although acne scars cause significant con-
cern for patients and clinicans alike, there is no 
standardised treatment protocol or indeed single 
modality used for all scar types. This is due in 
part to the variability in both presentation of the 
scars and also individual response to treatment. 
Furthermore, there is also variabilty seen in the 
resultant scarring that occurs in different patients 
from similar disease load. However, often the 
most severe scars result from severe inflamma-
tory nodulocystic acne but may also result from 
more superficial lesions. Erythema and pigmen-
tation changes represent epidermal damage 
whereas atrophic, hypertrophic and keloidal 
scars more frequently indicate dermal damage. 
Currently, there is no predictive tool to identify 
patients who are likely to develop acne scars. 
Despite this, there is general consensus that two 
key modifiable factors in acne scar formation are 
pivotal. These are the time delay between onset 
of effective treatment and the extent and dura-
tion of the inflammation. Therefore, in terms of 
acne scar prophylaxis, early appropriate medical 
Table 1. Post acne scars, qualitative global grading system (Goodman and Baron).
Grade Disease level Features and tests
I Macular These scars are erythematous, hyper- or hypopigmented macules. They do not represent a 
problem of contour but that of colour.
II Mild Mild atrophic or hypertrophic scars that may not be obvious at social distances of 0.5 m or greater 
and may be covered adequately by makeup or the normal shadow of shaved beard hair in men or 
normal body hair if extrafacial.
III Moderate Moderate atrophic or hypertrophic scarring that is obvious at social distances of 0.5 m or greater 
and is not covered easily by makeup or the normal shadow of shaved beard hair in men or body 
hair if extrafacial. Can be flattened by manual stretching of the skin (if atrophic).
VI Severe Severe atrophic or hypertrophic scarring that is evident at social distances greater than 0.5 m and 
is not covered easily by makeup or the normal shadow of shaved beard hair in men or body hair if 
extrafacial. Cannot be flattened by manual stretching of the skin.
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treatment that is continued for as long as neces-
sary is recommended.
Once atrophic acne scars are established and 
mature, a number of treatments have been advo-
cated. Many studies used to evaluate these tech-
niques are plagued by lack of adequate control 
groups, study sample size, objective outcome 
measures, time to follow-up and a combination 
of biases. Techniques with supportive level IV evi-
dence include resurfacing manouvres that 
destroy the epidermis and allow for collagenous 
remodelling. These include dermabrasion or 
microdermabrasion,98–100 light or medium-depth 
chemical peeling with either Jessner solution, 
20–35% trichloroacetic (as a spot or generalised 
peel) or glycolic acids99,101–103 and the use of vari-
ous laser technologies.99,104–106 Ablative lasers 
used have included both 10,600 nm CO2 and 
2940 nm erbium-doped yttrium-garnet (Er:YAG) 
lasers which have until recently been regarded as 
the gold standard.107–111 While effective in resur-
facing, these modalities have been limited by 
prolonged downtime with oedema, serous dis-
charge and erythema, post-inflammatory hyper-
pigmentation (PIH), hypopigmentation and the 
potential risk of worsening atrophic scars with 
over treatment in the form of further scar-
ring.112–114 These complications drove the quest 
for less-invasive laser resurfacing methods with 
non-ablative lasers. The most widely used of these 
are the 1320 nm neodymium:yttrium-aluminium-
garnet (Nd:YAG) and 1450 nm diode lasers.115–118 
More recently, fractionated photothermolysis 
through the use of fractional ablative CO2 laser 
therapy has been demonstrated to be efficacious 
in both case reports and non-controlled tri-
als119–125 with stronger evidence coming from two 
split-face randomised controlled trials.126,127
In terms of surgery, a number of approaches 
have been proposed. Level V evidence supports 
scar excision with or without elevation or graft-
ing. Punch biopsy, hair transplant punch or 
elliptical excision is often performed for ice pick 
and deep boxcar scars.94,129 Punch elevation is 
used for shallow and deep boxcar scars and graft-
ing for sharp walled or very deep ice pick 
scars.98,130 Subcision (percutaneously releasing 
fibrosis) with a tri-bevel bladed needle is 
supported by level VI evidence and is performed 
for rolling or depressed scars.131,132 An alterna-
tive to excision, is the correction of the contour 
deficit seen in the atrophic scars with filler. Level 
V evidence supports the use of synthetic and 
biological fillers for superficial, soft, sloping 
walled scars,102 but there is a risk of worsening 
the appearance of scars with underlying fibrotic 
tethering. Quite often, each of these modalities 
have been used in combination.88
Our unit’s approach to the treatment of 
atrophic acne scarring is to individually direct 
therapy on a case-by-case basis with the goal to 
improve scars rather than to deliver a complete 
cure resulting in a perfect complexion. Treatment 
depends on the extent and type of scars present 
and as such, the modality may vary within each 
facial cosmetic subunit. First, a comprehensive 
patient history is required which should include 
all pharmacological acne treatments including 
recent isotretinoin use and history of any keloid 
or hypertrophic scarring.
Surgical intervention within six months of 
the discontinuation of isotretinoin may result in 
hypertrophic scarring.133 Therefore, we perform 
no intervention within a 12-month period of 
stopping isotretinoin. Furthermore, if there is 
still active acne inflammation, medical treatment 
should be optimised in conjunction with primary 
care and dermatology. Such treatment can be 
divided into topical and systemic treatments and 
are often used in combination based on the cur-
rent European Acne guidelines134,135 (Table 2).
While medical treatment is being optimised, 
ice pick and boxcar scars are reconstructed by 
punch excision, under local anaesthetic or gen-
eral anasthesia. Disposable 1.0–3.0 mm punch 
biopsy instruments are used to excise ice pick 
scars, to include the shoulders of the scar, full 
thickness to subcutaneous fat. Boxcar scars are 
perpendicularly stab excised full thickness with a 
number 11 blade held backwards, to include the 
scar walls, following the shape of the scar. Polyfax 
ointment is used as a dressing. All boxcar and 
punch excisions 1.5 mm and above are closed 
with non-absorbable monofilament suture 
removed at postoperative day 5. Treated scars 
should be at least 5 mm apart to prevent traction 
on suturing and prevent adequate wound ever-
sion. Any scars larger than 3.5 mm are excised as 
an ellipse and closed parallel to relaxed skin ten-
sion lines. The goal is to exchange the visibly con-
toured acne scarring with less visible flat scars. 
After a test area to access the excisional scarring 
response, the technique is repeated in stages 
until all scars have been addressed.
Once acne inflammation and concurrent 
infection is quiescent, patients with Goodman and 
Baron grade III or VI scarring, with stretch cor-
rectable contour, fractionated photothermoloysis 
for facial resurfacing is performed by our unit. 
The Lumenis Ultrapulse® fractional ablative CO2 
laser (Lumenis Ltd., Yokneum, Israel) TotalFX® 
is used. To avoid dyschromia in Fitzpatrick 
phototypes ⩾ V, a simple bleaching mixture of 
0.025–0.05% Retin A, 4% hydroquinone and 1% 
hydrocortisone cream is commenced three to 
four weeks prior to treatment and continued for 
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two weeks after healing has been completed. 
For resistant hyperpigmentation, 0.01% Tretinoin 
and hydroquinone 4%, followed by a Kligmans 
trio preparation with 5% hydroquinone, 0.01% 
Fluocinolone and 0.05% Tretinoin is advised.
Up to 80% of the population will have a dor-
mant herpes labialis or herpes zoster infection. 
For CO2 laser treatments near the mouth, 
patients are administered viral prophylaxis to 
avoid reactivation and antibiotics to avoid post-
procedure infection.
The senior author advocates a three-step 
approach as shown in Schedule 1. At the base of 
the depression of the atrophic scar, the first pass 
uses the DeepFX® mode with a very small beam 
pattern to fit the scar ‘hole’. A fluence of 15–20 mJ 
or up to 30 mJ in very thick and oily skin is used 
with a density of 10% with a single pulse. The 
second pass uses the ActiveFX® mode with the 
non-sequential array (CoolScan) with a fluence 
of 50–60 mJ, density of 5–7 and rate of 450 Hz 
with the hand piece used at 45° to contour the 
shoulder of the depression with a small-sized 
beam pattern. An intermediary scrub of this pass 
is then performed to reveal superficial dermal 
capillaries in the pink papillary dermis. ActiveFX® 
mode is then used as a third pass over each entire 
scarred facial cosmetic subunit with a fluence of 
100 mJ, a density of 3 and a rate of 125 Hz. For 
more aggressive treatments between the second 
and the third pass, a further pass can be per-
formed using the DeepFX® mode micro scanner 
on all the areas affected by the acne scars with a 
fluence of 20–30 mJ, a density of 5–10% with a 
single pulse. Post procedure, a thin layer of 
petroleum-based ointment is applied, or if a gen-
eral anaesthetic has been used EMLA (eutectic 
mixture of lidocaine 2.5% and prilocaine 2.5%; 
Table 2. Summary of recommendations from the current European Acne treatment guideline,138,139 adapted from Rzany and 
Nast.136
Strength of 
evidence
Comedonal acne Mild–moderate 
papulopustular acne
Severe
papulopustular/
moderate nodular acne
Severe conglobate 
acne
High None Benzoyl peroxide + 
adapalene OR clindamycin
Isotretinoin* Isotretinoin*
Medium Topical retinoid† Azelaic acid or Benzoyl 
peroxide or topical retinoid† 
or systemic antibiotic‡ + 
adapalene§
Systemic antibiotics** + 
adapalene§ or systemic 
antibiotics** + azelaic 
acid†† or systemic 
antibiotics
+ adapalene + Benzoyl 
peroxide
Systemic antibiotics** 
+ azelaic acid
Low Azelaic acid
or Benzoyl peroxide
Blue light or oral zinc or 
topical erythromycin + 
isotretinoin or topical 
erythromycin + tretinoin or 
systemic antibiotic‡,**
+ Benzoyl peroxide‡‡ or 
systemic antibiotic‡,** + 
azelaic acid§ or systemic
antibiotics‡,** + adapalene 
+ Benzoyl peroxide§§
Systemic antibiotics** + 
Benzoyl peroxide‡‡
Systemic antibiotics** 
+ Benzoyl peroxide‡‡ 
or systemic
antibiotics** + 
adapalene§,§§
or systemic 
antibiotics**
+ adapalene + 
Benzoyl peroxide†
*Limitations can apply that may necessitate the use of a treatment with a lower strength of recommendation as a first-line therapy.
†Adapalene to be preferred over tretinoin/isotretinoin.
‡In case of more widespread disease/moderate severity, initiation of a systemic treatment can be recommended.
§Only studies found on systemic antibiotics + adapalene, Isotretinoin and tretinoin can be considered for combination treatment based on ex-
pert opinion. Further alternatives for women include hormonal antiandrogens and topical treatments or systemic antibiotics for severe papulo-
pustular/moderate nodular and severe nodular/conglobate acne.
**Doxycycline and lymecycline.
††Indirect evidence from nodular and conglobate acne and expert opinion.
‡‡Indirect evidence from a study also including chorhexidine, recommendation additionally based on expert opinion.
§§Indirect evidence from severe papulopustular acne.
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Figure 7. (a) Pre treatment and (b) post treatment.
Astra-Zeneca Pharmaceuticals, LP, London, UK) 
is applied followed by ice packs. Immediately post 
treatment erythema lasts for a few hours only and 
the sensation is similar to that of sunburn with a 
mild serous discharge. Once healed, the treated 
area will be red for six weeks to six months, but 
can be covered with makeup. The repeat treat-
ment interval is normally three months, if 
required. The postoperative care regimen is the 
same as that used in burns scar treatment.
Scheme 1: Acne technique with the fractional 
ablative CO2 laser.
A- First pass
B- Second pass
C- Third pass
Acne scarring
7. A 46-year-old woman, Fitzpatrick type II, 
with Grade VI Goodman and Baron Acne 
Vulgaris scarring presented. She had 
multiple ice pick, boxcar and cobble 
stoning scars over bilateral cheeks and 
forehead. Her inflammation was quies-
cent with no medication and she was oth-
erwise fit and well. She underwent two 
cycles of punch excision of the ice pick 
scars with 1.5, 2.0, 2.5, 3.0 and 4.0 mm 
punch biopsies. Punches over >2.0 mm 
were sutured with 5-0 Novafil and 
removed at postoperative day 5. A total of 
110 ice pick scars were excised. At a third 
stage one year later, ablative CO2 laser 
therapy was perfomed. All elevated scars 
were treated with multiple passes of 
Ultrapulse® 2 mm true spot hand piece 
175 mJ to flatten to the level of the 
surrounding epidermis. Fractional 
DeepFX® mode is then used at each of 
the scar bases 20 mL, 300 Hz, 2-10-1-10% 
and over each cosmetic subunit in its 
entirety at 20 mJ, 2-10-1-5% one pass. 
Finally, ActiveFX® mode was used over 
each scar shoulder 80 mJ, 3-5-1%.
8. A 44-year-old woman, Fitzpatrick type II, 
with Grade VI Goodman and Baron 
Acne Vulgaris scarring presented. She 
had multiple cobble stoning scars over 
bilateral cheeks and temporal regions. 
Her inflammation was quiescent with 
no medication and she was otherwise 
fit and well. She underwent two cycles 
of fractional ablative CO2 laser therapy. 
Fractional DeepFX® mode was used 
at each of the scar bases 20 mL, 300 Hz, 
2-10-1-10% and over each cosmetic 
subunit in its entirety at 20 mJ, 2-10-1-5% 
one pass. Finally, ActiveFX® mode was 
used over each scar shoulder 80 mJ, 
3-5-1%.
10 Scars, Burns & Healing
Pigmented and traumatic tattooed 
scars
Dyschromia within cutaneous scars is a result of 
abnormal melanogenesis.137 Eumelanin is a 
brown-black pigment found in higher ratios in 
darker skin types and those chronically exposed 
to ultraviolet radiation, and phaeomelanin is a 
red-brown pigment found in people with fair 
skin types. Critically, loss of adnexal melanocytic 
populations and the fundamental melanocytic 
immunomodulatory, anti-oxidative and anti-
inflammatory functions during wound healing is 
postulated to account for dyspigmentatory scar-
ring.138–140 Most commonly, this is seen as PIH in 
response to a variety of cutaneous insults.141
Prevention of dyschromia is critical. Therapy 
in tanned and dark skin types is considered on a 
case-by-case basis with appropriate risk counsel-
ling. Patients are warned of a worsening of pig-
mentation due to the potential hyperactivation 
of melanocytes and post-laser inflammatory 
response. Collateral bulk thermal injury is avoided 
with topical skin cooling; conservative starting 
treatment parameters, often with a small test 
patch, are performed and only when the effects of 
this test patch are apparent is treatment initiated 
cautiously with incremental fluence and density 
adjustments. If dyspigmentation does arise, depig-
mentation can be achieved medically or mechan-
ically. Chemical depigmentation includes a 
number of topical agents that work at different 
stages of melanogenesis to selectively bleach 
hyperactivated melanocytes. These stages include: 
(a) prior to melanin synthesis - the regulation of 
the transcription and activity of tyrosinase, tyrosi-
nerelated protein (TRP)-1 or 2, or peroxidase; 
(b) during melanin synthesis - by regulating the 
uptake and distribution of melanosomes in recipi-
ent keratinocytes; (c) after melanin synthesis - 
through melanin and melanosome degradation 
and processing of pigmented keratinocytes. The 
senior author advocates the use of tretinoin which 
acts via retinoid-activated transcription factors and 
interferes with melanocyte development and 
melanogenesis. It acts to both stimulate the differ-
entiation of melanocyte precursors, inducing 
transcription of tyrosinase by protein kinase C 
activation and microphthalmia transcription fac-
tor (MITF) expression, and removes differenti-
ated melanocytes by promoting apoptosis via 
caspase-3 pathway and bcl-2 down modulation.142 
In addition, it is felt that hydroquinone and azelaic 
acid derived from Pityrosporum Ovale, both of 
which inhibit tyrosinase activity during melanin 
synthesis, are useful additions to reduce pigmenta-
tion within a scar.
Dermabrasion, cryosurgery, chemical peeling 
and laser therapy143–146 as well as conventional 
surgical excision have been proposed to manage 
hyperpigmentation. In terms of laser therapy, 
selective melanin photothermolysis is achieved 
with a laser that has a wavelength in the absorp-
tion spectrum of melanin and sufficient energy 
levels to target melanosomes.147,148 Pulse duration 
should be less than the thermal relaxation of mel-
anin. Wavelengths less than 600 nm penetrate 
superficially with a lower fluence and thus can be 
used for epidermal hyperpigmentation, leaving 
deeper structures intact. Wavelengths longer than 
600 nm penetrate more deeply, require a greater 
fluence and thus can be used to target dermal 
pigmention. Energy delivery induces skin whiten-
ing due to thermal expansion within the melano-
somes leading to local vaporisation and acoustic 
waves that damage the nucleus and cause melano-
cytic apoptosis. Melanin that is subsequently 
released is processed through transepidermal 
elimination or through phagocytosis by dermal 
macrophages. Our unit uses short pulsed pig-
ment selective Q-switched alexandrite (755 nm 
Figure 8. (top) Pre treatment and (bottom) 12 months post 
last treatment.
McGoldrick et al. 11
wavelength) and Nd:YAG lasers (1064 nm) for 
dermally pigmented scars. For epidermal pig-
mentation, the frequency doubled Nd:YAG (532 
nm) and the fractional ablative (10,600 nm) CO2 
lasers are used.
Tattooed scars may result from commercial 
tattooing or traumatic injuries such as road traffic 
accidents or other encounters with asphault, 
explosives or pencil puncture wounds. In addi-
tion, they may result from surgical interventions 
involving inadvertent dermal inoculation. They 
are most frequently carbon-based and situated in 
the superficial dermis.149,150 Conventionally, these 
lesions have been treated with surgical excision or 
laser therapy with Q-switched systems.16 Our pref-
erence is to start treatment with either the 
Q-switched alexandrite (755 nm wavelength) or 
Nd:YAG lasers (1064 nm). The tattoo ink particles 
undergo photomechanical fragmentation which 
reduces both the dark scar colour and promi-
nence as there is a reduction in the inflammatory 
and granulomatous reaction driven by the pres-
ence of the foreign body.151 In some resistant 
cases, formal surgical excision of the tattooed 
scars or combination therapy is performed.
Pigmented and tattooed scars
9. A 55-year-old woman, Fitzpatrick type V, pre-
sented with hyperpigmented facial scars to 
her nose, cheeks and chin following small-
pox infection as a child. She was otherwise 
fit and well. She underwent two cycles of 
fractional ablative CO2 laser therapy. 
ActiveFX® mode was used over each scar 
cosmetic subunit with 175 mJ, 3-9-5 for two 
passes and edges were blended with 150 mJ, 
3-5-1. This was repeated on the nose and 
anterior cheeks two years later. Pre treat-
ment (top row) and 12 months post last 
treatment with a favourable resolution of 
the localised scar dyschromia (bottom row).
Figure 9. (top) Pre treatment and (bottom) 24 months post last treatment.
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10. A 43-year-old woman, Fitzpatrick type II, 
presented having developed hypertrophic 
scarring within a tattoo on the right breast 
following Rejuvi topical tattoo removal 
treatment. She was otherwise fit and well. 
She complained of intense pruritus, pain 
and of its unaesthetic appearance. She 
underwent two cycles of intralesional 
injection of 50 mg of 5-FU and 10 mg of 
Triamcinolone six weeks apart with good 
response. Thereafter, she underwent laser 
therapy with the Q-switched Alexandrite 
(755 nm) system with a fluence of 7.5 
Jcm–2, 10 Hz with a 2 mm spot. After three 
sessions over 20 months, the patient was 
satisfied with its appearance and resolu-
tion of symptoms.
Vascular and contoured scars
Cutaneous scars may exhibit persisting hypervas-
cularity as erythema or telangiectasia. During the 
proliferative phase of wound healing, VEGF stim-
ulates migratory endothelial cells with subse-
quent neoangiogenesis. This may persist for 
many months and can be treated with a variety of 
vascular lasers and non-coherent intense pulsed 
light (IPL) sources, all of which work on the prin-
ciple of selective photothermolysis. The chromo-
phore in a hypervascular scar is haemoglobin 
which in its erthrocytic oxyhaemoglobin state has 
a maximum peak absorption of 542 nm (α peak) 
and 577 nm (β peak). This can be selectively tar-
geted and damaged with minimal collateral dam-
age to surrounding tissues if the appropriate 
wavelength of light is used.152 The photothermol-
ysis induces a selective vascular injury with throm-
bosis, vessel wall necrosis and perivascular 
collagen damage with relatively little associated 
thermal injury in either the epidermis or sur-
rounding dermis.153
Vascular lasers include pulsed dye (585 and 
595 nm wavelength) and KTP-systems (532 nm), 
followed by longer wavelength lasers such as alex-
andrite lasers (755 nm), diode lasers (800–900 
nm) and the Nd:YAG lasers (1064 nm).154–158 IPL 
systems differ from lasers in that they simultane-
ously deliver multiple light wavelengths (500–
1200 nm) at different intensities. Lasers in 
contrast are monochromatic and offer the advan-
tage of high precision and peak power intensity.
1. Components: Gemini laser: Nd-YAG 1064 
for deep, KTP 532 for superficial, IPL
2. Special cases: tethered scars, pin cush-
ioned scars, webs.
Microbes in scar manipulation
Scar quality and scar burden differ significantly 
with the presence of infective entities. Infection 
is a well-established contributor to tissue volume 
loss, inflammation, destruction and organisa-
tion.156 Streptococcal species are associated with 
skin graft loss and consequently increased scar 
burden. For this reason, strategies dealing with 
prophylaxis of infection, early and effective treat-
ment are paramount to reducing the scar bur-
den, especially in the case of extensive disease 
processes such as large burns. Early diagnostics 
specific to invasive infection is an area of high 
clincal demand.157 Furthermore, an inadvertent 
source of delayed wound healing may be conven-
tional topical solutions applied to prevent or 
treat infection.162
It is also worth noting that some bacterial 
products are increasingly being recognised as 
potential therapeutics in multimodality scar 
management. Clostridium histolyticum colla-
genase is now established for the treatment of 
Dupuytren’s disease.163 Intralesional collagenase 
followed by compression has been described for 
ear keloids with some success.164
Conclusion
Scar management presents a significant chal-
lenge to the plastic surgeon. This two-part study 
summarised our Unit’s experience in multimo-
dality treatment, with particular reference to the 
hypertrophic spectrum, acne, pigmented and 
vascular scarring, based on the senior author’s 
experience spanning nearly 30 years and backed 
by evidence.
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Figure 10. (a) Pre treatment and (b) after intralesional 
injection and laser treatment.
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